114 related articles for article (PubMed ID: 22793378)
1. Limited-stage mantle cell lymphoma: treatment outcomes at the Princess Margaret Hospital.
Bernard M; Tsang RW; Le LW; Hodgson DC; Sun A; Wells W; Kukreti V; Kuruvilla J; Crump M; Gospodarowicz MK
Leuk Lymphoma; 2013 Feb; 54(2):261-7. PubMed ID: 22793378
[TBL] [Abstract][Full Text] [Related]
2. Mantle Cell Lymphoma Involving Skin: A Clinicopathologic Study of 37 Cases.
Kim DH; Medeiros LJ; Aung PP; Young KH; Miranda RN; Ok CY
Am J Surg Pathol; 2019 Oct; 43(10):1421-1428. PubMed ID: 31219818
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathologic features, management and outcomes of blastoid variant of mantle cell lymphoma: a Nebraska Lymphoma Study Group Experience.
Bhatt VR; Loberiza FR; Smith LM; Armitage JO; Greiner TC; Bast M; Lunning MA; Bierman PJ; Vose JM; Bociek RG
Leuk Lymphoma; 2016; 57(6):1327-34. PubMed ID: 26377137
[TBL] [Abstract][Full Text] [Related]
4. Limited-stage mantle-cell lymphoma.
Leitch HA; Gascoyne RD; Chhanabhai M; Voss NJ; Klasa R; Connors JM
Ann Oncol; 2003 Oct; 14(10):1555-61. PubMed ID: 14504058
[TBL] [Abstract][Full Text] [Related]
5. Highly effective local control and palliation of mantle cell lymphoma with involved-field radiation therapy (IFRT).
Rosenbluth BD; Yahalom J
Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):1185-91. PubMed ID: 16682133
[TBL] [Abstract][Full Text] [Related]
6. Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.
William BM; Allen MS; Loberiza FR; Bociek RG; Bierman PJ; Armitage JO; Vose JM
Biol Blood Marrow Transplant; 2014 Apr; 20(4):536-42. PubMed ID: 24434781
[TBL] [Abstract][Full Text] [Related]
7. Risk factors of central nervous system relapse in mantle cell lymphoma.
Conconi A; Franceschetti S; Lobetti-Bodoni C; Stathis A; Margiotta-Casaluci G; Ramponi A; Mazzucchelli L; Bertoni F; Ghielmini M; Gaidano G; Cavalli F; Zucca E
Leuk Lymphoma; 2013 Sep; 54(9):1908-14. PubMed ID: 23339449
[TBL] [Abstract][Full Text] [Related]
8. R-hyper-CVAD versus R-CHOP/cytarabine with high-dose therapy and autologous haematopoietic stem cell support in fit patients with mantle cell lymphoma: 20 years of single-center experience.
Widmer F; Balabanov S; Soldini D; Samaras P; Gerber B; Manz MG; Goede JS
Ann Hematol; 2018 Feb; 97(2):277-287. PubMed ID: 29147847
[TBL] [Abstract][Full Text] [Related]
9. Mantle cell lymphoma in the ocular adnexal region.
Looi A; Gascoyne RD; Chhanabhai M; Connors JM; Rootman J; White VA
Ophthalmology; 2005 Jan; 112(1):114-9. PubMed ID: 15629830
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma.
Mangel J; Buckstein R; Imrie K; Spaner D; Crump M; Tompkins K; Reis M; Perez-Ordonez B; Deodhare S; Romans R; Pennell N; Robinson JB; Hewitt K; Richardson P; Lima A; Pavlin P; Berinstein NL
Semin Oncol; 2002 Feb; 29(1 Suppl 2):56-69. PubMed ID: 11842390
[TBL] [Abstract][Full Text] [Related]
11. Management Trends and Outcomes for Stage I to II Mantle Cell Lymphoma Using the National Cancer Data Base: Ascertaining the Ideal Treatment Paradigm.
Gill BS; Vargo JA; Pai SS; Balasubramani GK; Beriwal S
Int J Radiat Oncol Biol Phys; 2015 Nov; 93(3):668-76. PubMed ID: 26461009
[TBL] [Abstract][Full Text] [Related]
12. Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years.
Kolstad A; Pedersen LB; Eskelund CW; Husby S; Grønbæk K; Jerkeman M; Laurell A; Räty R; Elonen E; Andersen NS; Brown PD; Kimby E; Bentzen H; Sundström C; Ehinger M; Karjalainen-Lindsberg ML; Delabie J; Ralfkiær E; Fagerli UM; Nilsson-Ehle H; Lauritzsen GF; Kuittinen O; Niemann C; Geisler CH;
Biol Blood Marrow Transplant; 2017 Mar; 23(3):428-435. PubMed ID: 28039078
[TBL] [Abstract][Full Text] [Related]
13. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network.
Hermine O; Hoster E; Walewski J; Bosly A; Stilgenbauer S; Thieblemont C; Szymczyk M; Bouabdallah R; Kneba M; Hallek M; Salles G; Feugier P; Ribrag V; Birkmann J; Forstpointner R; Haioun C; Hänel M; Casasnovas RO; Finke J; Peter N; Bouabdallah K; Sebban C; Fischer T; Dührsen U; Metzner B; Maschmeyer G; Kanz L; Schmidt C; Delarue R; Brousse N; Klapper W; Macintyre E; Delfau-Larue MH; Pott C; Hiddemann W; Unterhalt M; Dreyling M;
Lancet; 2016 Aug; 388(10044):565-75. PubMed ID: 27313086
[TBL] [Abstract][Full Text] [Related]
14. Addition of bortezomib to standard dose chop chemotherapy improves response and survival in relapsed mantle cell lymphoma.
Furtado M; Johnson R; Kruger A; Turner D; Rule S
Br J Haematol; 2015 Jan; 168(1):55-62. PubMed ID: 25146720
[TBL] [Abstract][Full Text] [Related]
15. Induction chemotherapy followed by concurrent chemoradiation in advanced squamous cell carcinoma of the head and neck: final results from a phase II study with docetaxel, cisplatin and 5-fluorouracil with a four-year follow-up.
Rapidis AD; Trichas M; Stavrinidis E; Roupakia A; Ioannidou G; Kritselis G; Liossi P; Giannakouras G; Douzinas EE; Katsilieris I
Oral Oncol; 2006 Aug; 42(7):675-84. PubMed ID: 16731029
[TBL] [Abstract][Full Text] [Related]
16. Variability in morphology and cell proliferation in sequential biopsies of mantle cell lymphoma at diagnosis and relapse: clinical correlation and insights into disease progression.
Vogt N; Klapper W
Histopathology; 2013 Jan; 62(2):334-42. PubMed ID: 23240716
[TBL] [Abstract][Full Text] [Related]
17. A retrospective analysis of outcomes for primary mediastinal large B-cell lymphoma treated with RCHOP followed by radiotherapy or front-line autologous stem cell transplantation.
Liu X; Deng T; Guo X; Guo Y; Wang L; Zhang J; Xia Z; Zhang Q; Xue K; Cao J; Shi J; Hong X
Hematology; 2017 Jun; 22(5):258-264. PubMed ID: 27884092
[TBL] [Abstract][Full Text] [Related]
18. [Mantle cell lymphoma: clinicopathologic features and prognostic factors of 102 cases occurring in Chinese patients].
Ji H; Li GD; Li FY; Bai YQ; Chen Y; Yang MZ; Wang LJ; Tang Y; Zhang P; Xia T; Li C; Feng J; Zou ZK; Yixi JC
Zhonghua Bing Li Xue Za Zhi; 2007 Nov; 36(11):730-5. PubMed ID: 18307875
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcome for patients with early stage marginal zone lymphoma and mantle cell lymphoma.
Barzenje DA; Holte H; Fosså A; Ghanima W; Liestøl K; Delabie J; Kolstad A
Leuk Lymphoma; 2017 Mar; 58(3):623-632. PubMed ID: 27389974
[TBL] [Abstract][Full Text] [Related]
20. Centroblastic-centrocytic non-Hodgkin's lymphoma stage I-III: patterns of failure following radiotherapy.
Frank C; Zierhut D; Schulz-Ertner D; Wannenmacher M
Strahlenther Onkol; 2001 Nov; 177(11):597-603. PubMed ID: 11757182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
